New COVID drug which cuts risk of death and hospitalisation by 79% approved for use in UK

UK

A new drug which can reduce the risk of hospitalisation and death from COVID by 79% has been approved for use in the UK for people aged 12 and up.

Xevudy – also known as sotrovimab – has been given the greenlight by the Medicines and Healthcare products Regulatory Agency (MHRA) after being found to cut the risk of serious illness in high-risk adults who had COVID symptoms.

The drug was developed by London-based GlaxoSmithKline in conjunction with Vir Biotechnology in California – and the makers say preclinical data shows the drug “retains activity against key mutations of the new Omicron variant”.

Live COVID updates from UK and around the world

But the MHRA has said it is too early to confirm this.

George Scangos, Vir chief executive, said: “Sotrovimab was deliberately designed with a mutating virus in mind.

“By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to address both the current Sars-CoV-2 virus and future variants that we expected would be inevitable.”

More on Covid-19

In a statement, the MHRA said: “Like molnupiravir, [Xevudy] has been authorised for use in people who have mild to moderate COVID-19 infection and at least one risk factor for developing severe illness.

“Such risk factors include obesity, older age (over 60 years), diabetes mellitus, or heart disease.

MUST CREDIT GSK/Vir Biotechnology Another COVID-19 treatment, Xevudy (sotrovimab), has today been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease.
Image:
The new drug is administered by intravenous infusion over 30 minutes. Pic: GSK/Vir Biotechnology

“Unlike molnupiravir, sotrovimab is administered by intravenous infusion over 30 minutes.

“It is approved for individuals aged 12 and above who weigh more than 40kg.

“It is too early to know whether the Omicron variant has any impact on sotrovimab’s effectiveness but the MHRA will work with the company to establish this.”

Dr June Raine, MHRA chief executive, said: “This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19, and signals another significant step forward in our fight against this devastating disease.

Follow the Daily podcast on Apple Podcasts, Google Podcasts, Spotify, Spreaker

“With no compromises on quality, safety and effectiveness, the public can trust that the MHRA have conducted a robust and thorough assessment of all the available data.”

The UK has ordered around 100,000 doses of sotrovimab.

Products You May Like

Articles You May Like

InMotion unveils ‘fastest in the world’ 87 MPH V13 Challenger electric unicycle
Many of these children could be treated – but doctors are struggling to keep them alive
How to watch PGA Tour’s FedEx St. Jude Championship on ESPN+
Energy bills expected to hit £4,200 in January, according to dire new forecast
Armie Hammer’s aunt to ‘reveal the dark twisted secrets of the family’ in new series

Leave a Reply

Your email address will not be published.